Abstract
In recent years, nanoparticulate-mediated drug delivery research has examined a full spectrum of nanoparticles that can be used in diagnostic and therapeutic cancer applications. A key aspect of this technology is in the potential to specifically target the nanoparticles to diseased cells using a range of molecules, in particular antibodies. Antibody-nanoparticle conjugates have the potential to elicit effective targeting and release of therapeutic targets at the disease site, while minimizing off-target side effects caused by dosing of normal tissues. This article provides an overview of various antibody-conjugated nanoparticle strategies, focusing on the rationale of cell-surface receptors targeted and their potential clinical application.
| Original language | English |
|---|---|
| Pages (from-to) | 381-394 |
| Number of pages | 14 |
| Journal | Immunotherapy |
| Volume | 3 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Mar 2011 |
ASJC Scopus subject areas
- Immunology and Allergy
- Oncology
- Immunology
